Heidelberg Pharma AG (HPHA.DE) Comparison with companies in other sectors?

Heidelberg Pharma AG has a share price of 46.60M. You can analyze Heidelberg Pharma AG (HPHA.DE) competitors across different market sectors through stock heatmaps.

What are HPHA.DE's NET and operating margins?

Heidelberg Pharma AG (HPHA.DE) operating margin is around -3.74, and net profit margin is approximately -3.04 as of the latest reports.

In what way does HPHA.DE's earnings per share (EPS) trend reflect its financial momentum?

Heidelberg Pharma AG (HPHA.DE) EPS is -0.50 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Heidelberg Pharma AG is -8.38, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Heidelberg Pharma AG?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Heidelberg Pharma AG like P/E which is -9.38, P/B which is 7.79, and PEG which is 1.31. Compare them with sector averages to evaluate if the stock is priced fairly.

Heidelberg Pharma AG

HPHA.DE•XETRA

Healthcare

Biotechnology

€4.19

€0.01(0.24%)

Heidelberg Pharma AG (HPHA.DE) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.50

P/E Ratio

-8.38

ROE

-0.63%

Net Margin

-3.04%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$195.26M

Shares OutstandingTotal number of shares issued

$46.60M

Book Value/ShareNet worth per share

$0.54

Revenue/ShareAnnual revenue per share

$0.15

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.5

Net MarginNet income as percentage of revenue

-303.90%

Operating MarginOperating income as percentage of revenue

-373.97%

ROEReturn on shareholders' equity

-62.67%

ROAReturn on total assets

-39.44%

ROCEReturn on capital employed

-54.24%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.60

Cash/ShareCash and equivalents per share

$0.44

FCF YieldFree cash flow as percentage of market cap

-14.31%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for HPHA.DEFinancial Ratios Analysis details for HPHA.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HPHA.DESector Benchmarking details for HPHA.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Heidelberg Pharma AG Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Heidelberg Pharma AG. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Heidelberg Pharma AG's unique business strengths and challenges.

Key Financial Metrics for Heidelberg Pharma AG

For Heidelberg Pharma AG, essential financial indicators include EPS -0.50, PE -8.38, and ROE -0.63. These key ratios reveal insights into Heidelberg Pharma AG's profitability, valuation, and operational health. Understanding these metrics enables you to compare Heidelberg Pharma AG with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Heidelberg Pharma AG

Metrics like Net Margin -303.90% and ROA -39.44% shed light on how well Heidelberg Pharma AG is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Heidelberg Pharma AG can sustain its operations and continue growing in the future.

Valuation and Market Position of Heidelberg Pharma AG

Using ratios such as P/B Ratio 7.79 and PEG Ratio 1.31, investors can assess whether Heidelberg Pharma AG is appropriately valued based on its financials and growth potential. These figures, combined with Heidelberg Pharma AG's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Heidelberg Pharma AG

Financial health indicators, such as Debt/Equity Ratio 0.006 and Cash Flow $-0.60, provide a snapshot of Heidelberg Pharma AG's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Heidelberg Pharma AG, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Heidelberg Pharma AG

Investing in Heidelberg Pharma AG based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Heidelberg Pharma AG focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;